Collecting Nektar

Given the potential of NKTR-214 to broaden the reach of checkpoint inhibitors, four buysiders who spoke with BioCentury said they would not be surprised to see Nektar Therapeutics (NASDAQ:NKTR) acquired, despite the 130% run-up in the company’s stock in recent months.

“It has cornerstone potential in an area of huge unmet need where larger players are seemingly willing to bet their farms,” said LSP’s Joep Muijrers, who is not a Nektar shareholder...